Little is known about the molecular machinery that contributes to site-specific copy number variations or how CNVs fit into the chronology of tumor progression. Black et al. (2013) now demonstrate that the overexpression of a histone demethylase induces transient copy gain of specific genomic loci known to harbor proto-oncogenes.
Little is known about the molecular machinery that contributes to site-specific copy number variations or how CNVs fit into the chronology of tumor progression. Black et al. (2013) now demonstrate that the overexpression of a histone demethylase induces transient copy gain of specific genomic loci known to harbor proto-oncogenes.
DNA replication is a tightly regulated and highly coordinated process that minimizes incorporation of mismatched nucleotides and ensures that each DNA strand is faithfully replicated exactly once per cell cycle. This vital task is shared between thousands of separate replicons to accommodate timely genome replication (Pope et al., 2013) . Molecular analyses of replication demonstrate that not all replicons behave the same in regard to replication timing during S phase. Transcriptionally active, gene-rich domains replicate during the first half of S phase (early), whereas transcriptionally repressed, gene-poor loci replicate in the second half of S phase (late). Furthermore, alterations in replication timing accompany key stages of development (Hiratani et al., 2009) .
In addition to diverse roles of histone modifications in the regulation of gene expression (Lee et al., 2010) , there are close links between posttranslational histone modifications and the cell cycle (Schulze et al., 2009) . Studies utilizing chromatin immunoprecipitation followed by next-generation sequencing (ChIPseq) suggest a role for covalent chromatin modifications in regulating early versus late replicating domains (Schwaiger et al., 2009 ). It has also been hypothesized that DNA replication is regulated at the chromatin level, where histone modifications recruit factors that impede DNA replication (Black et al., 2010) . Chromatin regions lacking these histone modifications are more accessible to the replication machinery and are therefore more likely to be mistakenly rereplicated. In a previous study, Whetstine and colleagues demonstrated that the levels of KDM4A/JMJD2, a histone H3K9 and H3K36-specific demethylase, are regulated during S phase and that KDM4A overexpression increases chromatin accessibility while altering replication timing of specific genomic loci (Black et al., 2010) . In this issue, they demonstrate that KDM4A overexpression induces copy number gains at specific loci, such as 1q12, which contain putative oncogenes (Black et al., 2013) . Though KDM4A overexpression was previously reported in a small set of cancers (Mallette and Richard, 2012) , Black and colleagues extend this list by analyzing the Cancer Genome Atlas (TCGA) for tumors containing increased KDM4A copy numbers and expression levels (Black et al., 2013) . They identify ovarian cancer as being significantly enriched for KDM4A copy number amplification in 46% of the tumor samples. Although they were unable to detect copy gains by spectral karyotyping, upon reanalyzing previous KDM4A ChIP-chip data, they identify enrichments for cytogenetic bands such as 1q12 as a result of KDM4A overexpression. Fluorescent in situ hybridization (FISH) experiments in KDM4A-overexpressing cells confirm the copy number increase while ruling out whole-chromosome duplications. Importantly, this site-specific copy gain coamplifies with KDM4A in primary tumor samples.
To investigate the molecular mechanism linking KDM4A and copy number variation (CNV), Black et al., overexpress KDM4A point mutants and find that the Jumonji catalytic domain and both Tudor domains are required for CNV. To exclude the possibility that KDM4A functions through a histone-independent pathway, the authors coexpress histone H3 mutants with methionine in place of either lysine 9 or 36 (H3K9M, H3K36M). Histone mutants that interfere with H3K9/36 methylation recapitulate the KDM4A-dependent CNV phenotype, indicating that KDM4A histone-demethylase activity plays a direct role in this process. Additionally, KDM4A immunoprecipitation resulted in the identification of interacting proteins such as members of the minichromosome maintenance (MCM) complex and several DNA polymerase subunits. The authors speculate that KDM4A promotes unlicensed replication via bypassing the need for the origin of replication complex (ORC) formation via direct MCM and DNA polymerase recruitment ( Figure 1) .
Previously, Black et al. identified HP1g as an antagonist of KDM4A-dependent S-phase progression (Black et al., 2010) . Here, they further characterize this antagonism by showing that HP1g overexpression disrupts KDM4A-dependent CNV. HP1g contains a chromodomain that binds methylated histone H3K9. Therefore, HP1g is able to block KDM4A demethylation, creating a ''steric blockade'' that prevents local DNA replication. Consistent with this hypothesis, overexpression of H3K9 methyltransferase Suv39h1/KMT1A is also able to suppress 1q12 copy gains.
Finally, to determine whether 1q12 copy gains are stably inherited by daughter cells, single-cell clones from KDM4A-overexpressing cell lines were generated. Strikingly, when performing 1q12 FISH, only 17% of cells contain the 1q12 copy gain, indicating that KDM4A-dependent copy gains are not stably inherited by daughter cells. By arresting KDM4A-overexpressing cells at either G1/S or G2, it was determined that copy gains are generated during S phase but disappear by G2 via an undetermined mechanism. This suggests that the copy gains are not incorporated into the genome but, rather, exist as extrachromosomal DNA. Intriguingly, the 1q12/21 regions contain several proto-oncogenes, including Mcl1 and Bcl9, and this region is frequently amplified in lung cancer and multiple myeloma. In addition, 1q12/21 copy gains are associated with drug resistance in ovarian cell lines and multiple myeloma, underscoring the significance of understanding the relationship between KDM4A and 1q12/ 21 coamplification in human health.
Chromosome copy number alterations are thought to be important for acquired cellular plasticity by allowing a precancerous cell to amplify genes that are required for proliferation, angiogenesis, and evasion of cell death. The discovery of KDM4A overexpression as a driver of CNV has uncovered a potential mechanistic link between local chromatin structure/composition and DNA rereplication with copy number variation. Histone H3K9 trimethylation, the substrate for KDM4A, is associated with both active and repressed gene states. A role for histone H3K9 methylation and HP1-g in this process is very exciting; however, it is unclear whether KDM4A's role in cancer pathogenesis is due to its function at heterochromatin or through the transcriptional elongation regulatory function associated with H3K9 trimethylation. Among the three isoforms of HP1 (a, b, and g), HP1-g is found on transcriptionally active regions (Smith and Shilatifard, 2007) . Because KDM4A demethylates histone H3K36, a chromatin mark associated with the elongating and active form of RNA polymerase II (Smith and Shilatifard, 2007) , a role for the misregulation of transcription elongation control in cancer pathogenesis through CNV as a result of KDM4A overexpression should also be considered. Indeed, aberrant transcriptional elongation checkpoint control has been proposed as a key regulatory mechanism for leukemic pathogenesis through chromosomal translocations and other forms of cancer (Smith and Shilatifard, 2013 replication and genome stability. The very exciting identification of KDM4A overexpression and its association with ovarian cancer clearly has provided the field with yet another chromatin-modifying enzyme that can be used as a possible therapeutic target.
